id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-P-6024-0008,FDA,FDA-2025-P-6024,Final Response,Other,Denial,2026-05-15T04:00:00Z,2026,5,2026-05-15T04:00:00Z,,2026-05-16T01:50:33Z,,0,0,09000064b92dc6f6
FDA-2025-P-6024-0007,FDA,FDA-2025-P-6024,Completeness Assessment Correspondence,Other,Assessment Document or Analysis,2025-12-01T05:00:00Z,2025,12,2025-12-01T05:00:00Z,,2025-12-01T20:24:41Z,,0,0,09000064b90a5838
FDA-2025-P-6024-0004,FDA,FDA-2025-P-6024,Attachment 2 - Clemastine Fumarate labeling,Supporting & Related Material,Background Material,2025-11-12T05:00:00Z,2025,11,,,2025-11-13T01:55:07Z,,0,0,09000064b907deb2
FDA-2025-P-6024-0005,FDA,FDA-2025-P-6024,Attachment 3 - Tavist labeling,Supporting & Related Material,Background Material,2025-11-12T05:00:00Z,2025,11,,,2025-11-13T01:55:09Z,,0,0,09000064b907deb9
FDA-2025-P-6024-0002,FDA,FDA-2025-P-6024,"Acknowledgement Letter from FDA DMB to Hyman, Phelps & McNamara, P.C.",Other,Acknowledgement Letter/Receipt,2025-11-12T05:00:00Z,2025,11,2025-11-12T05:00:00Z,,2025-11-13T01:53:32Z,,0,0,09000064b907de38
FDA-2025-P-6024-0001,FDA,FDA-2025-P-6024,"Suitability Petition from Hyman, Phelps & McNamara, P.C.",Other,Petition(s),2025-11-12T05:00:00Z,2025,11,2025-11-12T05:00:00Z,,2025-11-13T01:50:10Z,,1,0,09000064b907de37
FDA-2025-P-6024-0003,FDA,FDA-2025-P-6024,Attachment 1 - Tavist OB listing,Supporting & Related Material,Background Material,2025-11-12T05:00:00Z,2025,11,,,2025-11-13T01:55:05Z,,0,0,09000064b907dea8
FDA-2025-P-6024-0006,FDA,FDA-2025-P-6024,Attachment 4 - Draft Clemastine Fumarate labeling,Supporting & Related Material,Background Material,2025-11-12T05:00:00Z,2025,11,,,2025-11-13T01:55:11Z,,0,0,09000064b907debb